Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer. Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
Metrics to compare | CURAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCURASPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.1x | −2.7x | −0.7x | |
PEG Ratio | −0.28 | −0.04 | 0.00 | |
Price/Book | 8.5x | 1.7x | 2.6x | |
Price / LTM Sales | - | 16.0x | 3.4x | |
Upside (Analyst Target) | 43.9% | 349.1% | 35.5% | |
Fair Value Upside | Unlock | −4.1% | 3.3% | Unlock |